Literature DB >> 30850208

Adoptive Cell Therapy: ACT-Up or ACT-Out?

Malcolm K Brenner1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30850208      PMCID： PMC6453505          DOI： 10.1016/j.ymthe.2019.02.017

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  6 in total

1.  Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow.

Authors:  J Z Wimperis; M K Brenner; H G Prentice; J E Reittie; P Karayiannis; P D Griffiths; A V Hoffbrand
Journal:  Lancet       Date:  1986-02-15       Impact factor: 79.321

Review 2.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

3.  Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.

Authors:  Claudia Rossig; Catherine M Bollard; Jed G Nuchtern; Cliona M Rooney; Malcolm K Brenner
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

4.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

5.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Authors:  Martin A Pule; Barbara Savoldo; G Doug Myers; Claudia Rossig; Heidi V Russell; Gianpietro Dotti; M Helen Huls; Enli Liu; Adrian P Gee; Zhuyong Mei; Eric Yvon; Heidi L Weiss; Hao Liu; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Nat Med       Date:  2008-11-02       Impact factor: 53.440

6.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors:  C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321
  6 in total
  2 in total

Review 1.  Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar.

Authors:  Bella Guerrouahen; Muhammad Elnaggar; Anjud Al-Mohannadi; Dhanya Kizhakayil; Chiara Bonini; Reuben Benjamin; Renier Brentjens; Christian J Buchholz; Giulia Casorati; Soldano Ferrone; Frederick L Locke; Francisco Martin; Axel Schambach; Cameron Turtle; Paul Veys; Hans J van der Vliet; Cristina Maccalli
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

Review 2.  Application of double-negative T cells in haematological malignancies: recent progress and future directions.

Authors:  Xingchi Chen; Dongyao Wang; Xiaoyu Zhu
Journal:  Biomark Res       Date:  2022-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.